Nu-Med Plus Selects Tom Tait as VP of Scientific Advancement and to Their Board of Directors

SALT LAKE CITY, UT--(Marketwired - Apr 14, 2015) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device company which explores and develops medical applications of new technologies in the medical field, announced the appointment of Tom Tait to their Board of Directors and correspondingly an Officer of the Company.

Mr. Tait holds an MBA in Technology Management and a BS in Chemistry from Clarkson University. He also holds patents in Optics and MEMS technologies along with multiple publications and citations in the chemical literature. Mr. Tait has been involved in several successful endeavors that have resulted in improved products or new product categories. Mr. Jeff Robins, President and CEO of Nu-Med Plus, commented, "Mr. Tait's background spans 35 years in the chemical industry filling countless management positions with a successful record. Mr. Tait's contributions and value to our company as a consultant were significant. The Company feels he will be an instrumental addition to our management team and should be vital in the areas of business planning and advancement of existing and new technology."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more information please visit

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Contact Information:


Jeff Robins